Takeda laid off 243 remote U.S. employees, a strategic move tied to an upcoming drug exclusivity loss, according to BioSpace. Similarly, Exelixis cut 130 staff companywide, including 33 remote workers, planning to reopen many as on-site roles, also per BioSpace. These layoffs highlight a corporate drive to reduce remote workforces and mandate a return to office.
Companies often cite collaboration and AI as reasons for these remote job cuts. Yet, many roles are being offshored or eliminated for pure cost-cutting. This creates a tension between stated corporate goals and actual operational strategies, signaling a clear shift away from fully remote models by 2026.
The current wave of remote job cuts suggests a corporate pivot towards cost optimization and increased control, potentially at the expense of worker flexibility and genuine innovation.
Widespread Cuts Across Industries
ADC Therapeutics cut approximately 30% of its global workforce to trim costs and extend its cash runway, according to BioSpace. Acrisure also announced it would cut 2,250 jobs, about 11% of its workforce, through 2027, according to The Detroit News. These significant reductions across diverse sectors confirm a broad corporate restructuring, indicating a strategic shift beyond isolated incidents.
The Shifting Rationales: Cost, Control, and Collaboration
Former Acrisure employees reported their positions were offshored after layoffs, according to The Detroit News. This occurred as EMD Serono emphasized in-person work for collaboration and scientific discovery, according to BioSpace. While collaboration is a common justification, these contrasting actions reveal a dual strategy: companies like Exelixis and EMD Serono are strategically dismantling remote work, often using 'collaboration' as a shield for cost-cutting and a return to less flexible structures.
